Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Spero Therapeutics Inc
SPROCurrent price
0.73 USD
+0.0002 USD (+0.03%)
Last closed
0.73 USD
Company
sperotherapeutics.com
ISIN
US84833T1034
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
40 527 936 USD
Yield for 12 month
-49.64 %
1Y
3Y
5Y
10Y
15Y
SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Address: 675 Massachusetts Avenue, Cambridge, MA, United States, 02139
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5.00 USDP/E ratio
–Dividend Yield
–Current Year
+47 977 000 USD
Last Year
+96 735 000 USD
Current Quarter
+9 356 000 USD
Last Quarter
+13 469 000 USD
Current Year
+47 977 000 USD
Last Year
+96 368 000 USD
Current Quarter
+9 356 000 USD
Last Quarter
+13 469 000 USD
Key Figures SPRO
1 year
3 years
5 years
10 years
EBITDA
-72 482 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-30.93 %
PEG Ratio
–
Return On Equity TTM
-89.62 %
Wall Street Target Price
5.00 USD
Revenue TTM
47 977 000 USD
Book Value
0.85 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-79.50 %
Dividend Yield
–
Gross Profit TTM
-48 780 000 USD
Earnings per share
-1.27 USD
Diluted Eps TTM
-1.27 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
75.30 %
Profit Margin
-142.91 %
Dividend Analytics SPRO
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History SPRO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation SPRO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.14
Price Sales TTM
0.84
Enterprise Value EBITDA
0.75
Price Book MRQ
0.88
Financials SPRO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators SPRO
For 52 weeks
0.51 USD
1.72 USD
50 Day MA
0.75 USD
Shares Short Prior Month
437 248
200 Day MA
1.09 USD
Short Ratio
4.22
Shares Short
498 066
Short Percent
1.08 %
BeatStart